Clinical Trial Search

Primary: Percentage of Participants With Transient Hypoparathyroidism, as Defined by a Day 1 Serum Parathyroid Hormone (PTH) Level of < 10 pg/ml — 24.1; 33.3 percentage of…

Primary: Primary Efficacy Parameters of Sensitivity of High Resolution Magnetic Resonance Imaging With Lymphotrophic Superparamagnetic Nanoparticles (LSN MRI) — 85.5 percentage…

Primary: Percentage of Participants With Local-regional Progression-free Survival — 15.2 percentage of all participants

Primary: Percentage of Participants With Objective Response (OR) — 38.3 Percentage of participants

Primary: The Rate of Successful Thyroid Ablation as Defined by Negative Recombinant Human Thyrotropin (rhTSH) Stimulated Radioiodine Whole Body Scan (RAI WBS) at 1 Year. — 10; 10…

Primary: Objective Response Rate, Assessed Using the Response Evaluation Criteria in Solid Tumors (RECIST) — 9; 7 Participants — p=<0.10

Primary: Best Overall Response Rate — 9.4; 0; 30 percentage of participants

Primary: Progression-free Survival (PFS) Based on Central Assessment Incl. Clinical Progression Due to Bone Irradiation — 329; 175 Days — p=<0.0001

Primary: Progression Free Survival — 241 days

Primary: Tumor Response (Change) — 6.0; 3.9 cm

Primary: Overall Response Rate — 11 Participants

Primary: Median Progression Free Survival — 12.5 months

Primary: Change in Tumor Size — 4.7 cm

Primary: Number of Persons That Are Vitamin D Deficient in the Thyroid Nodule, Thyroid Cancer in Remission, and the Active Thyroid Cancer Groups. — 23; 20; 11 participants…

Primary: Maximum Tolerated Dose (MTD) [Phase I Dose Escalation] — 5 mg

Primary: Objective Tumor Response Rate at 3, 6, and 12 Months — 0; 0; 12; 13 participants

Primary: Restoration of Radioiodine Uptake in Metastatic Lesions as Demonstrated by Diagnostic Whole-body Scanning After Decitabine Administration — 0 participants

Primary: Number of Participants With Response Per Responsive Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) — 17; 9; 11 Participants

Primary: PET-CT Fusion Scanning Sensitivity — 49; 54 percentage of participants

Primary: Objective Response Rate (ORR) — 1 Participants

Primary: Response Rate — 17 Participants

Primary: Proportion of Patients Who Have Remained on Treatment and Progression-free at Least One Year After Start of 17-AAG (Tanespimycin) — 5.9; 12.5 percentage of participants

Primary: Response at 6 Months — 7; 2 Participants — p=0.0787

Primary: Overall Response (OR) — 0; 3; 3; 1 Participants

Primary: Increased Radioiodine Uptake — 6 Participants

Primary: Objective Tumor Response Rate Assessed by RECIST — 0 participants

Primary: Objective Response Rate of Sorafenib Tosylate in Metastatic Medullary Thyroid Carcinoma in Setting of Inherited Tumor Syndromes as Well as in Setting of Sporadic…

Primary: Changes in Thyroid Nodule Size — 0.241361; 0.954909; 0.422121; 0.104143 mL

Primary: Tumor Major Response Rate (Including Stable Disease) as Measured by RECIST Criteria — 10; 1 participants

Primary: Percentage of Participants With Objective Response (OR) — 34.6 percentage of participants